ClinicalTrials.gg
CompletedNCT05321082Updated Jan 9, 2026Results posted

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

A Phase 3 interventional study of BI 1015550 and Placebo in Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim. Completed at 400 sites in 45 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,178
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim — 4 open to participants now, 6 under way, 4 of them phase 3. Lung Diseases, Interstitial · Boehringer Ingelheim.

Enrollment
Largest of 12
1,178 · median 248
Started
2022
with 3 others
Phase 3
11 of 24
3 open now
Registered
13th of 24
by date

Among the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2022, is one of 11 in phase 3, and was the 13th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

4 of the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue treatment throughout the study.

The purpose of this study is to find out whether a medicine called BI 1015550 helps people with PF-ILD. Participants are put into 3 groups randomly, which means by chance. Participants in 2 groups take different doses of BI 1015550 as tablets twice a day. Participants in the placebo group take placebo tablets twice a day. Placebo tablets look like BI 1015550 tablets but do not contain any medicine.

Participants are in the study for up to two and a half years. During the first year, they visit the study site 10 times. Afterwards, they visit the study site every 3 months. The doctors regularly test participants' lung function. The results of the lung function tests are compared between the groups. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Lung Diseases, Interstitial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years old at the time of signed .
  2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
  3. Diagnosis of progressive fibrosing ILD other than IPF (physician confirmed).
  4. Patients may be either:

    • on a stable therapy* with nintedanib for at least 12 weeks prior to Visit 1 and during screening and are planning to stay on this background treatment after randomization. (*stable therapy is defined as a tolerated regimen of nintedanib (with no dose changes) for at least 12 weeks)
    • not on treatment with nintedanib for at least 8 weeks prior to Visit 1 and during the screening period (e.g. either Antifibrotic (AF)-treatment naïve or previously discontinued) and do not plan to start or re-start antifibrotic treatment.
  5. Forced Vital Capacity (FVC) ≥45% of predicted normal at Visit 1.
  6. DLCO ≥25% of predicted normal corrected for (Hb) at Visit 1.
  7. Women of (WOCBP) must be ready and able to use highly effective methods of . WOCBP taking oral contraceptives (OCs) also have to use one barrier method
  8. Patients treated with permitted agents (other than ) for an underlying systemic disease (e.g. Methotrexate (MTX), Azathioprine (AZA)) need to be on a stable treatment for at least 12 weeks prior to Visit 1 and during the screening period.

Exclusion criteria

Exclusion criteria

  1. Prebronchodilator (FEV1)/Forced vital capacity (FVC) \<0.7 at Visit 1
  2. In the opinion of the Investigator, other pulmonary abnormalities.
  3. Acute Interstitial Lung Disease (ILD) exacerbation within 3 months prior to Visit 1 and/or during the screening period (investigator-determined).
  4. Relevant chronic or acute infections including (HIV) and viral hepatitis.
  5. Patients having developed ILD due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/coronavirus disease 2019 (COVID-19) within 12 months of screening (based on investigators judgement).
  6. Major surgery (major according to the investigator's assessment) performed within 6 weeks prior to Visit 2 or planned during the trial period, e.g. hip replacement. Registration on lung transplantation list would not be considered as planned major surgery.
  7. Any documented active or suspected or history of malignancy within 5 years prior to Visit 1, except appropriately treated basal cell carcinoma of the skin, in situ squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  8. (AST) or Alanine Aminotransferase (ALT) >2.5 x (ULN) or total >1.5 x ULN at Visit 1.

Further exclusion criteria apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,178 participants (actual)

Study arms

  • Experimental
    Nerandomilast 9 mg

    Patients with progressive fibrosing interstitial lung disease (PF-ILD) or progressive pulmonary fibrosis (PPF), other than idiopathic pulmonary fibrosis (IPF), were administered 9 milligrams (mg) nerandomilast, taken orally as film-coated tablets twice daily (18 mg total), in the morning and in the evening for an initial 52 weeks, followed by a variable duration till end of trial.

    Drug: BI 1015550

  • Experimental
    Nerandomilast 18 mg

    Patients with progressive fibrosing interstitial lung disease (PF-ILD) or progressive pulmonary fibrosis (PPF), other than idiopathic pulmonary fibrosis (IPF), were administered 18 mg nerandomilast, taken orally as film-coated tablets twice daily (36 mg total), in the morning and in the evening for an initial 52 weeks, followed by a variable duration till end of trial.

    Drug: BI 1015550

  • Placebo comparator
    Placebo

    Patients with progressive fibrosing interstitial lung disease (PF-ILD) or progressive pulmonary fibrosis (PPF), other than idiopathic pulmonary fibrosis (IPF), were administered placebo matching nerandomilast, taken orally as film-coated tablets twice daily, in the morning and in the evening for an initial 52 weeks, followed by a variable duration till end of trial.

    Drug: Placebo

Interventions

  • Participants received film-coated nerandomilast tablets orally, twice daily, at doses of either 9 mg or 18 mg, in the morning and in the evening.

    Also known as: Nerandomilast, JASCAYD®

  • DrugPlacebo

    Participants received placebo matching 9 mg or 18 mg nerandomilast film-coated tablets orally, twice daily, in the morning and in the evening.

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52

    The absolute change from baseline in forced vital capacity (FVC) in milliliters \[mL\] at Week 52 is reported. The absolute change from baseline in FVC was analyzed by a restricted maximum likelihood (REML)-based mixed model with repeated measurements (MMRM) comparing the change from baseline in FVC at Week 52 between treatment groups. The analysis included the fixed, categorical effects of treatment, baseline intake of antifibrotic (AF) treatment, and baseline High-resolution Computed Tomography (HRCT) pattern at each visit, as well as the fixed continuous effects of baseline FVC value at each visit. Visits were treated as a repeated measure with an unstructured covariance structure used to model within-patient measurements.

    Time frame: The MMRM model is a longitudinal analysis, and it incorporated FVC measurements change from baseline at Week 1, Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. Data presented is the FVC adjusted change from baseline at Week 52.

Secondary outcomes

  1. Key Secondary Endpoint: Time to First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute ILD Exacerbation, First Hospitalisation for Respiratory Cause, or Death (Whichever Occurred First) Over the Duration of the Trial

    Time to first occurrence of any of the components of the composite endpoint - acute interstitial lung disease (ILD) exacerbation, first hospitalisation for respiratory cause, or death (whichever occurred first) - is reported as the number of participants who experienced any of these events during the trial. Acute exacerbation of ILD describes an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality with all of the following: Acute worsening or development of dyspnea typically with less than 1 month duration, computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILD, and deterioration not fully explained by cardiac failure or fluid overload. If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute ILD exacerbation, hospitalization, death.

    Time frame: From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.

  2. Time to First Acute ILD Exacerbation or Death Over the Duration of the Trial

    Time to first acute ILD exacerbation or death over the duration of the trial is reported as the number of patients who experienced either event. Acute exacerbation of ILD describes an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality with all of the following: Acute worsening or development of dyspnea typically with less than 1 month duration, computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILD, and deterioration not fully explained by cardiac failure or fluid overload. If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute IPF exacerbation followed by death.

    Time frame: From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.

  3. Time to Hospitalisation for Respiratory Cause or Death Over the Duration of the Trial

    Time to hospitalisation for respiratory cause or death over the duration of the trial is reported as the number of participants who experienced either event. Hospitalizations due to respiratory causes were recorded on a specific non-elective hospitalization CRF page. This page captured the hospitalization date, confirmation of a respiratory cause, and the primary admission diagnosis. Time to death was based either on the date of death on the adverse event (AE) report for patients with AEs leading to death or was based on the information from the vital status assessment.

    Time frame: From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.

  4. Time to Death Over the Duration of the Trial

    Time to death over the duration of the trial is reported as the number of participants who died. Time to death was based either on the date of death on the AE report for patients with AEs leading to death or based on the information from the vital status assessment.

    Time frame: From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.

  5. Absolute Change From Baseline in Forced Vital Capacity (FVC) Percent (%) Predicted at Week 52

    Absolute change from baseline in forced vital capacity (FVC) percent (%) predicted at Week 52 is reported. Analysis was based on a Mixed Model for Repeated Measures (MMRM), with fixed, categorical effects of treatment at each visit, baseline antifibrotic therapy at each visit, baseline HRCT pattern at each visit, the fixed continuous effects of baseline FVC \[% pred\] at each visit and unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were used as covariates.

    Time frame: The MMRM model is a longitudinal analysis, and it incorporated FVC % predicted change from baseline at Week 1, Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. Data presented is change from baseline in FVC % predicted at Week 52.

  6. Time to Absolute Decline in Forced Vital Capacity (FVC) % Predicted of >10% From Baseline or Death Over the Duration of the Trial

    The time to absolute decline of more than 10% from baseline in forced vital capacity (FVC) percent predicted, or death, over the duration of the trial is reported as the number of participants who experienced either event. If multiple components occurred on the day of first event, then the patient was only counted in the first component based on the following hierarchy: absolute decline in FVC % predicted of \> 10% followed by death.

    Time frame: From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.

  7. Absolute Change From Baseline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) % Predicted (Corrected for Hb) at Week 52

    The absolute change from baseline in Diffusing Capacity of the Lungs for Carbon Monoxide percent predicted (corrected for hemoglobin, Hb) at Week 52 is reported.. Analysis was based on a Mixed Model for Repeated Measures (MMRM), with fixed, categorical effects of treatment at each visit, baseline antifibrotic therapy at each visit, baseline HRCT pattern at each visit, the fixed continuous effects of baseline DLCO \[% pred\] at each visit and unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were used as covariates.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated DLCO measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, and Week 52. The data represent the adjusted Least Square Means for change from baseline at Week 52.

  8. Time to Absolute Decline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Percentage Predicted by More Than 15% From Baseline or Death, Measured Over the Duration of the Trial

    Time to absolute decline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) percentage predicted by more than 15% from baseline or death, measured over the duration of the trial is reported as the number of participants who experienced either event. The Predicted DLCO value was corrected for hemoglobin (Hb). If more than one component occurred on the same day, the patient was counted under the first event according to the hierarchy: Absolute decline in DLCO % predicted of \> 15%, followed by Death.

    Time frame: From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.

  9. Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52

    The absolute change from baseline in Living with Pulmonary Fibrosis (L-PF) Symptoms Dyspnea domain score at Week 52 is reported. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnoea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, baseline HRCT pattern, and fixed continuous effect of baseline L-PF dyspnea score at each visit, with an unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were covariates.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the adjusted Least Square Means for change from baseline at Week 52.

  10. Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52

    The absolute change from baseline in the L-PF Cough domain score at Week 52 is reported. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, baseline HRCT pattern, and fixed continuous effect of baseline L-PF dyspnea score at each visit, with an unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were covariates.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the adjusted Least Square Means for change from baseline at Week 52.

  11. Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Fatigue Domain Score at Week 52

    The absolute change from baseline in the L-PF Fatigue domain score at Week 52 is reported. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, and baseline HRCT pattern at each visit, and fixed continuous effect of baseline L-PF Fatigue score at each visit, with an unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were covariates.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the adjusted Least Square Means for change from baseline at Week 52.

07

Results

Posted Jan 9, 2026

Participant flow

This was a multi-centre, multi-national, prospective, randomised, placebo-controlled, double-blind clinical trial, including a treatment period of at least 52 weeks, and a 1-week follow-up period in patients with progressive pulmonary fibrosis. The trial comprised two parts: Treatment Period A lasted up to 52 weeks post-randomisation, followed by Treatment Period B in which patients continued randomised blinded treatment for a variable duration.

Participant flow — Overall Study
MilestonePlaceboNerandomilast 9 mgNerandomilast 18 mg
Started393393392
Treated392393391
Completed treatment up to 52 weeks317318311
Completed271283272
Not completed122110120
Withdrew: Other than listed402627
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject303442
Withdrew: Protocol violation001
Withdrew: Adverse event494948
Withdrew: Lack of efficacy201
Withdrew: Not treated101

Outcome measures

SecondaryKey Secondary Endpoint: Time to First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute ILD Exacerbation, First Hospitalisation for Respiratory Cause, or Death (Whichever Occurred First) Over the Duration of the Trial

Time to first occurrence of any of the components of the composite endpoint - acute interstitial lung disease (ILD) exacerbation, first hospitalisation for respiratory cause, or death (whichever occurred first) - is reported as the number of participants who experienced any of these events during the trial. Acute exacerbation of ILD describes an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality with all of the following: Acute worsening or development of dyspnea typically with less than 1 month duration, computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILD, and deterioration not fully explained by cardiac failure or fluid overload. If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute ILD exacerbation, hospitalization, death.

Time frame:
From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.
Reported as:
Count of participants · Participants
Key Secondary Endpoint: Time to First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute ILD Exacerbation, First Hospitalisation for Respiratory Cause, or Death (Whichever Occurred First) Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mgNerandomilast 18 mg
Acute ILD exacerbation as first event443430
Hospitalisation for respiratory cause as first event827074
Death as first event17129
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Regression, Cox · p = 0.0507 · Hazard ratio (hr): 0.78 · 95% CI 0.61 to 1.00
  • Placebo vs Nerandomilast 18 mg · Regression, Cox · p = 0.0395 · Hazard ratio (hr): 0.77 · 95% CI 0.60 to 0.99
SecondaryTime to First Acute ILD Exacerbation or Death Over the Duration of the Trial

Time to first acute ILD exacerbation or death over the duration of the trial is reported as the number of patients who experienced either event. Acute exacerbation of ILD describes an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality with all of the following: Acute worsening or development of dyspnea typically with less than 1 month duration, computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILD, and deterioration not fully explained by cardiac failure or fluid overload. If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute IPF exacerbation followed by death.

Time frame:
From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.
Reported as:
Count of participants · Participants
Time to First Acute ILD Exacerbation or Death Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mgNerandomilast 18 mg
Acute ILD exacerbation574635
Death402424
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Regression, Cox · p = 0.0258 · Hazard ratio (hr): 0.70 · 95% CI 0.51 to 0.96
  • Placebo vs Nerandomilast 18 mg · Regression, Cox · p = 0.0017 · Hazard ratio (hr): 0.59 · 95% CI 0.43 to 0.82
SecondaryTime to Hospitalisation for Respiratory Cause or Death Over the Duration of the Trial

Time to hospitalisation for respiratory cause or death over the duration of the trial is reported as the number of participants who experienced either event. Hospitalizations due to respiratory causes were recorded on a specific non-elective hospitalization CRF page. This page captured the hospitalization date, confirmation of a respiratory cause, and the primary admission diagnosis. Time to death was based either on the date of death on the adverse event (AE) report for patients with AEs leading to death or was based on the information from the vital status assessment.

Time frame:
From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.
Reported as:
Count of participants · Participants
Time to Hospitalisation for Respiratory Cause or Death Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mgNerandomilast 18 mg
Hospitalization for respiratory cause1139094
Death18139
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Regression, Cox · p = 0.0237 · Hazard ratio (hr): 0.74 · 95% CI 0.57 to 0.96
  • Placebo vs Nerandomilast 18 mg · Regression, Cox · p = 0.0427 · Hazard ratio (hr): 0.76 · 95% CI 0.59 to 0.99
PrimaryAbsolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52

The absolute change from baseline in forced vital capacity (FVC) in milliliters \[mL\] at Week 52 is reported. The absolute change from baseline in FVC was analyzed by a restricted maximum likelihood (REML)-based mixed model with repeated measurements (MMRM) comparing the change from baseline in FVC at Week 52 between treatment groups. The analysis included the fixed, categorical effects of treatment, baseline intake of antifibrotic (AF) treatment, and baseline High-resolution Computed Tomography (HRCT) pattern at each visit, as well as the fixed continuous effects of baseline FVC value at each visit. Visits were treated as a repeated measure with an unstructured covariance structure used to model within-patient measurements.

Time frame:
The MMRM model is a longitudinal analysis, and it incorporated FVC measurements change from baseline at Week 1, Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. Data presented is the FVC adjusted change from baseline at Week 52.
Reported as:
Least squares mean · Milliliters (mL)
Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52
Milliliters (mL)PlaceboNerandomilast 9 mgNerandomilast 18 mg
Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52-165.77 (-190.52 to -141.03)-84.64 (-109.63 to -59.65)-98.59 (-123.74 to -73.44)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (net): 81.14 · 95% CI 45.95 to 116.32Adjusted mean difference in FVC change from baseline at Week 52 between the Nerandomilast 9 mg group and the Placebo group.
  • Placebo vs Nerandomilast 18 mg · Mixed Models Analysis · p = 0.0002 · Mean difference (net): 67.18 · 95% CI 31.91 to 102.46Adjusted mean difference in FVC change from baseline at Week 52 between the Nerandomilast 18 mg group and the Placebo group.
SecondaryTime to Death Over the Duration of the Trial

Time to death over the duration of the trial is reported as the number of participants who died. Time to death was based either on the date of death on the AE report for patients with AEs leading to death or based on the information from the vital status assessment.

Time frame:
From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.
Reported as:
Count of participants · Participants
Time to Death Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mgNerandomilast 18 mg
Time to Death Over the Duration of the Trial643634
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Regression, Cox · p = 0.0017 · Hazard ratio (hr): 0.51 · 95% CI 0.34 to 0.78
  • Placebo vs Nerandomilast 18 mg · Regression, Cox · p = 0.0018 · Hazard ratio (hr): 0.51 · 95% CI 0.34 to 0.78
SecondaryAbsolute Change From Baseline in Forced Vital Capacity (FVC) Percent (%) Predicted at Week 52

Absolute change from baseline in forced vital capacity (FVC) percent (%) predicted at Week 52 is reported. Analysis was based on a Mixed Model for Repeated Measures (MMRM), with fixed, categorical effects of treatment at each visit, baseline antifibrotic therapy at each visit, baseline HRCT pattern at each visit, the fixed continuous effects of baseline FVC \[% pred\] at each visit and unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were used as covariates.

Time frame:
The MMRM model is a longitudinal analysis, and it incorporated FVC % predicted change from baseline at Week 1, Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. Data presented is change from baseline in FVC % predicted at Week 52.
Reported as:
Least squares mean · FVC percent predicted
Absolute Change From Baseline in Forced Vital Capacity (FVC) Percent (%) Predicted at Week 52
FVC percent predictedPlaceboNerandomilast 9 mgNerandomilast 18 mg
Absolute Change From Baseline in Forced Vital Capacity (FVC) Percent (%) Predicted at Week 52-4.88 (-5.61 to -4.15)-2.69 (-3.43 to -1.95)-2.94 (-3.68 to -2.19)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (net): 2.19 · 95% CI 1.15 to 3.23The adjusted mean difference represents the model-estimated difference in predicted Forced Vital Capacity % between the Nerandomilast 9 mg group and the Placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg · Mixed Models Analysis · p = 0.0003 · Mean difference (net): 1.94 · 95% CI 0.90 to 2.98The adjusted mean difference represents the model-estimated difference in predicted Forced Vital Capacity % between the Nerandomilast 18 mg group and the Placebo group at Week 52.
SecondaryTime to Absolute Decline in Forced Vital Capacity (FVC) % Predicted of >10% From Baseline or Death Over the Duration of the Trial

The time to absolute decline of more than 10% from baseline in forced vital capacity (FVC) percent predicted, or death, over the duration of the trial is reported as the number of participants who experienced either event. If multiple components occurred on the day of first event, then the patient was only counted in the first component based on the following hierarchy: absolute decline in FVC % predicted of \> 10% followed by death.

Time frame:
From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.
Reported as:
Count of participants · Participants
Time to Absolute Decline in Forced Vital Capacity (FVC) % Predicted of >10% From Baseline or Death Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mgNerandomilast 18 mg
Absolute decline in FVC % predicted of > 10%13095100
Death393024
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Regression, Cox · p = 0.0018 · Hazard ratio (hr): 0.69 · 95% CI 0.54 to 0.87
  • Placebo vs Nerandomilast 18 mg · Regression, Cox · p = 0.0038 · Hazard ratio (hr): 0.71 · 95% CI 0.56 to 0.89
SecondaryAbsolute Change From Baseline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) % Predicted (Corrected for Hb) at Week 52

The absolute change from baseline in Diffusing Capacity of the Lungs for Carbon Monoxide percent predicted (corrected for hemoglobin, Hb) at Week 52 is reported.. Analysis was based on a Mixed Model for Repeated Measures (MMRM), with fixed, categorical effects of treatment at each visit, baseline antifibrotic therapy at each visit, baseline HRCT pattern at each visit, the fixed continuous effects of baseline DLCO \[% pred\] at each visit and unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were used as covariates.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated DLCO measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, and Week 52. The data represent the adjusted Least Square Means for change from baseline at Week 52.
Reported as:
Least squares mean · DLCO percent (%) predicted
Absolute Change From Baseline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) % Predicted (Corrected for Hb) at Week 52
DLCO percent (%) predictedPlaceboNerandomilast 9 mgNerandomilast 18 mg
Absolute Change From Baseline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) % Predicted (Corrected for Hb) at Week 52-2.48 (-3.89 to -1.07)-3.38 (-4.80 to -1.96)-2.97 (-4.40 to -1.53)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Mixed Models Analysis · p = 0.3793 · Mean difference (net): -0.90 · 95% CI -2.90 to 1.11The adjusted mean difference represents the model-estimated difference in DLCO \[% pred\] between the Nerandomilast 9 mg group and the Placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg · Mixed Models Analysis · p = 0.6354 · Mean difference (net): -0.49 · 95% CI -2.50 to 1.53The adjusted mean difference represents the model-estimated difference in DLCO \[% pred\] between the Nerandomilast 18 mg group and the Placebo group at Week 52.
SecondaryTime to Absolute Decline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Percentage Predicted by More Than 15% From Baseline or Death, Measured Over the Duration of the Trial

Time to absolute decline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) percentage predicted by more than 15% from baseline or death, measured over the duration of the trial is reported as the number of participants who experienced either event. The Predicted DLCO value was corrected for hemoglobin (Hb). If more than one component occurred on the same day, the patient was counted under the first event according to the hierarchy: Absolute decline in DLCO % predicted of \> 15%, followed by Death.

Time frame:
From first administration of trial drug (Nerandomilast or Placebo) till end of study, up to 26.2 months.
Reported as:
Count of participants · Participants
Time to Absolute Decline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Percentage Predicted by More Than 15% From Baseline or Death, Measured Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mgNerandomilast 18 mg
Absolute decline in DLCO % predicted of > 15%495352
Death583532
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Regression, Cox · p = 0.2967 · Hazard ratio (hr): 0.86 · 95% CI 0.65 to 1.14
  • Placebo vs Nerandomilast 18 mg · Regression, Cox · p = 0.4815 · Hazard ratio (hr): 0.90 · 95% CI 0.68 to 1.20
SecondaryAbsolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52

The absolute change from baseline in Living with Pulmonary Fibrosis (L-PF) Symptoms Dyspnea domain score at Week 52 is reported. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnoea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, baseline HRCT pattern, and fixed continuous effect of baseline L-PF dyspnea score at each visit, with an unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were covariates.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the adjusted Least Square Means for change from baseline at Week 52.
Reported as:
Least squares mean · Score on a scale
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52
Score on a scalePlaceboNerandomilast 9 mgNerandomilast 18 mg
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 525.75 (4.04 to 7.46)4.87 (3.15 to 6.58)4.48 (2.76 to 6.20)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Mixed Models Analysis · p = 0.4748 · Mean difference (net): -0.88 · 95% CI -3.30 to 1.54The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Dyspnea score) between the Nerandomilast 9mg group and the Placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg · Mixed Models Analysis · p = 0.3042 · Mean difference (net): -1.27 · 95% CI -3.69 to 1.15The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Dyspnea score) between the Nerandomilast 18 mg group and the Placebo group at Week 52.
SecondaryAbsolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52

The absolute change from baseline in the L-PF Cough domain score at Week 52 is reported. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, baseline HRCT pattern, and fixed continuous effect of baseline L-PF dyspnea score at each visit, with an unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were covariates.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the adjusted Least Square Means for change from baseline at Week 52.
Reported as:
Least squares mean · Score on a scale
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52
Score on a scalePlaceboNerandomilast 9 mgNerandomilast 18 mg
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 523.05 (0.79 to 5.31)1.17 (-1.09 to 3.44)3.19 (0.92 to 5.46)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Mixed Models Analysis · p = 0.2506 · Mean difference (net): -1.88 · 95% CI -5.08 to 1.33The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Cough score) between the Nerandomilast 9 mg group and the Placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg · Mixed Models Analysis · p = 0.9311 · Mean difference (net): 0.14 · 95% CI -3.07 to 3.35The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Cough score) between the Nerandomilast 18 mg group and the Placebo group at Week 52.
SecondaryAbsolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Fatigue Domain Score at Week 52

The absolute change from baseline in the L-PF Fatigue domain score at Week 52 is reported. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, and baseline HRCT pattern at each visit, and fixed continuous effect of baseline L-PF Fatigue score at each visit, with an unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were covariates.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the adjusted Least Square Means for change from baseline at Week 52.
Reported as:
Least squares mean · Score on a scale
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Fatigue Domain Score at Week 52
Score on a scalePlaceboNerandomilast 9 mgNerandomilast 18 mg
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Fatigue Domain Score at Week 522.95 (1.18 to 4.73)3.01 (1.23 to 4.78)3.89 (2.11 to 5.68)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg · Mixed Models Analysis · p = 0.9668 · Mean difference (net): 0.05 · 95% CI -2.46 to 2.57The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Fatigue score) between the Nerandomilast 9mg group and the Placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg · Mixed Models Analysis · p = 0.4644 · Mean difference (net): 0.94 · 95% CI -1.58 to 3.46The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Fatigue score) between the Nerandomilast 18 mg group and the Placebo group at Week 52.

Adverse events

Collected over Serious and Other adverse events, All-cause mortality: From first drug administration until end of trial, plus a residual effect period of 7 days, up to 26.4 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo64/392 (16.3%)198/392 (50.5%)320/392 (81.6%)
Nerandomilast 9 mg36/393 (9.2%)174/393 (44.3%)324/393 (82.4%)
Nerandomilast 18 mg34/391 (8.7%)182/391 (46.5%)333/391 (85.2%)
Most frequent serious events
Showing 10 of 363
Most frequent serious events
EventPlaceboNerandomilast 9 mgNerandomilast 18 mg
Condition aggravatedGeneral disorders54/39241/39327/391
PneumoniaInfections and infestations32/39237/39335/391
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders15/3929/39312/391
Respiratory failureRespiratory, thoracic and mediastinal disorders14/39210/39310/391
PneumothoraxRespiratory, thoracic and mediastinal disorders13/3928/3936/391
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders10/3927/3938/391
COVID-19Infections and infestations9/3927/3936/391
DyspnoeaRespiratory, thoracic and mediastinal disorders9/3926/3933/391
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders5/3927/3932/391
DeathGeneral disorders6/3925/3936/391
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlaceboNerandomilast 9 mgNerandomilast 18 mg
DiarrhoeaGastrointestinal disorders107/392129/393151/391
Upper respiratory tract infectionInfections and infestations71/39251/39355/391
CoughRespiratory, thoracic and mediastinal disorders63/39259/39368/391
Weight decreasedInvestigations36/39244/39358/391
COVID-19Infections and infestations57/39248/39354/391
DepressionPsychiatric disorders54/39245/39351/391
NasopharyngitisInfections and infestations53/39254/39351/391
AnxietyPsychiatric disorders50/39246/39353/391
NauseaGastrointestinal disorders30/39236/39350/391
DyspnoeaRespiratory, thoracic and mediastinal disorders39/39240/39342/391

Baseline characteristics

Full Analysis Set (FAS): This patient set included all randomised patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analysed as their randomised treatment group.

Age, Continuous
Age, Continuous(Years)PlaceboNerandomilast 9 mgNerandomilast 18 mgTotal
Mean66.6 ± 10.366.5 ± 9.866.0 ± 9.866.4 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNerandomilast 9 mgNerandomilast 18 mgTotal
Female161190171522
Male231203220654
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboNerandomilast 9 mgNerandomilast 18 mgTotal
Hispanic or Latino536057170
Not Hispanic or Latino3393333341006
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboNerandomilast 9 mgNerandomilast 18 mgTotal
American Indian or Alaska Native56213
Asian149155143447
Native Hawaiian or Other Pacific Islander0000
Black or African American73616
White226224235685
More than one race55515
Unknown or Not Reported0000
Forced vital capacity (FVC) at baseline
Forced vital capacity (FVC) at baseline(Milliliters (mL))PlaceboNerandomilast 9 mgNerandomilast 18 mgTotal
Mean2353.6 ± 766.22325.5 ± 767.62381.4 ± 722.82353.4 ± 752.3
08

Study locations

400 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Christiana Hospital
    Newark, Delaware 19718, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • University of Florida Health Shands Hospital
    Gainesville, Florida 32610, United States
  • Clinical Research Specialists LLC
    Kissimmee, Florida 34746, United States
  • Advanced Pulmonary Research Institute
    Loxahatchee Groves, Florida 33470, United States
  • Destin Pulmonary Critical Care
    Santa Rosa Beach, Florida 32459, United States
  • Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead
    Atlanta, Georgia 30309, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Evanston Hospital Pulmonary Clinic
    Evanston, Illinois 60201, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21224, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • St. Elizabeth's Medical Center
    Boston, Massachusetts 02135, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Infinity Medical Research
    North Dartmouth, Massachusetts 02747, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109-5314, United States
  • Beaumont Health
    Royal Oak, Michigan 48073, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic, Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Renown Regional Medical Center
    Reno, Nevada 89502, United States
  • Stony Brook University Medical Center
    Commack, New York 11725, United States
  • Lenox Hill Hospital
    New York, New York 10021, United States
  • Columbia University Medical Center-New York Presbyterian Hospital
    New York, New York 10032, United States
  • NewYork-Presbyterian/Weill Cornell Medical Center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Southeastern Research Center-Winston-Salem-61365
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • The Oregon Clinic
    Portland, Oregon 97220, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Jefferson Health Honickman Center
    Philadelphia, Pennsylvania 19107, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Infinity Medical Research, Inc.
    East Providence, Rhode Island 02914, United States
  • Lowcountry Lung and Critical Care
    Charleston, South Carolina 29406, United States
  • Clinical Trials Center of Middle Tennessee, LLC
    Franklin, Tennessee 37067, United States
  • Vanderbilt University Medical Center - Vanderbilt Lung Institute at 100 Oaks
    Nashville, Tennessee 37204, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Premier Pulmonary Critical Care and Sleep Medicine
    Denison, Texas 75020, United States
  • UT Health San Antonio
    San Antonio, Texas 78229, United States
  • Intermountain Medical Center-Murray-69497
    Murray, Utah 84107, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84108, United States
  • University of Vermont
    Burlington, Vermont 05401, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Centro de Investigaciones Metabolicas (CINME)-C.A.B.A-61553
    C.a.b.a, 1056, Argentina
  • CEDIC - Centro de Investigacion Clinica
    CABA, C1060ABN, Argentina
  • Hospital Italiano de Buenos Aires
    CABA, C1199ABB, Argentina
  • Consultorios Médicos del Buen Ayre
    Capital Federal, 1425, Argentina
  • APRILLUS-Asistencia e Investigacion
    Ciudad Autonoma Buenos Aires, C1046AAQ, Argentina
  • CEMER-Centro Medico De Enfermedades Respiratorias
    Florida, B1602DQD, Argentina
  • Instituto Ave Pulmo
    Mar del Plata, 7600, Argentina
  • INSARES
    Mendoza, M5500CCG, Argentina
  • Centro Respiratorio de Quilmes
    Quilmes, B1878FNR, Argentina
  • Instituto Médico de la Fundación Estudios Clínicos
    Rosario, S2000DEJ, Argentina
  • Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Royal Prince Alfred Hospital
    Camperdown, Sydney, New South Wales 2050, Australia
  • Macquarie University
    Macquarie Park, New South Wales 2109, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Lung Research Queensland
    Chermside, Queensland 4032, Australia
  • The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Mater Hospital Brisbane
    South Brisbane, Queensland 4101, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Lung Research Victoria
    Footscray, Victoria 3011, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • Trialswest
    Spearwood, Western Australia 6163, Australia
  • Medical University of Graz State Hospital - University Hospital Graz
    Graz, 8036, Austria
  • LKH Klagenfurt am Woerthersee
    Klagenfurt, 9020, Austria
  • Krems University Hospital
    Krems, 3500, Austria
  • Hospital Elisabethinen Linz
    Linz, Austria
  • LKH Salzburg University Hospital
    Salzburg, 5020, Austria
  • AKH - Medical University of Vienna
    Vienna, 1090, Austria
  • Standort Penzing der Klinik Ottakring
    Vienna, 1140, Austria
  • Clinic Floridsdorf
    Vienna, 1210, Austria
  • Klinikum Wels - Grieskirchen GmbH
    Wels, 4600, Austria
  • Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim
    Antwerp, 2020, Belgium
  • ULB Hopital Erasme
    Brussels, 1070, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, 4000, Belgium
  • Yvoir - UNIV UCL de Mont-Godinne
    Yvoir, 5530, Belgium
  • Serviços Medicos Respirar Sul Fluminense
    Barra Mansa, 27323240, Brazil
  • Hospital das Clinicas da Universidade Federal de Minas Gerais (HCUFMG)
    Belo Horizonte,Minas Gerais, 31270901, Brazil

Showing the first 100 of 400 sites across 45 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wuyts WA, Richeldi L, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Martinez FJ, Valenzuela C, Wijsenbeek MS, Kanakapura M, James A, Weimann G, Drzewuski C, Coeck C, Maher TM. Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER-ON). BMC Pulm Med. 2025 Dec 4;26(1):10. doi: 10.1186/s12890-025-03973-7. PubMed 41345848 ↗
  • Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ; FIBRONEER-ILD Trial Investigators. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12;392(22):2203-2214. doi: 10.1056/NEJMoa2503643. Epub 2025 May 19. PubMed 40388329 ↗
  • Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Coeck C, Schlecker C, Voss F, Wachtlin D, Martinez FJ. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respir Res. 2023 Sep;10(1):e001580. doi: 10.1136/bmjresp-2022-001580. PubMed 37709661 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Dec 2024, 25 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2022
First posted
Apr 11, 2022
StartActual
Nov 16, 2022
Primary completionActual
Dec 18, 2024
CompletionActual
Apr 14, 2025
Results first posted
Jan 9, 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05321082
Responsible party
Sponsor
First posted
Apr 11, 2022
Start date
Nov 16, 2022
Primary completion
Dec 18, 2024
Completion
Apr 14, 2025
Results posted
Jan 9, 2026
Last update
Jan 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion